NDAORALCAPSULE2 Generics Approved
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
18
Data completeness
4/8 — Partial
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vyvanse (lisdexamfetamine dimesylate) is an oral capsule-based central nervous system stimulant approved in 2007 for ADHD treatment. It is a prodrug that is metabolized to active dextroamphetamine, providing sustained therapeutic effect with a once-daily dosing regimen. The drug addresses symptoms of inattention and hyperactivity-impulsivity in both pediatric and adult populations.
$139MPart D
LOE ApproachingProduct approaching loss of exclusivity with significant revenue base; commercial teams are likely focused on life-cycle extension strategies and defending market share against generic entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Started Sep 2025
105 enrolled
Obesity and OverweightBinge Eating Disorder
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
Started Jun 2019
150 enrolled
Binge-eating Disorder
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Started Jan 2014
418 enrolled
Binge Eating Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
Started Apr 2012
464 enrolled
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
Started Apr 2012
549 enrolled
Attention-deficit/Hyperactivity Disorder
Worked on VYVANSE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.